Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial

Robert J. Motzer; Paul Russo; Naomi Haas; Christian Doehn; Frede Donskov; Marine Gross-Goupil; Sergei Varlamov; Evgeny Kopyltsov; Jae Lyun Lee; Ho Yeong Lim; Bohuslav Melichar; Milada Zemanova; Brian Rini; Toni K. Choueiri; Lori Wood; M. Neil Reaume; Arnulf Stenzl; Simon Chowdhury; Ray McDermott; Agnieszka Michael; Miguel Izquierdo; Paola Aimone; Hong Zhang; Cora N. Sternberg

Journal Article

Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial

European Urology (2021) 79(3) 334-338

DOI: 10.1016/j.eururo.2020.12.029

63Citations

52Readers

Get full text

Abstract

Adjuvant pazopanib does not extend overall survival compared to placebo in patients with locally advanced or metastatic renal cell carcinoma.

Author supplied keywords

Cite

CITATION STYLE

APA

Motzer, R. J., Russo, P., Haas, N., Doehn, C., Donskov, F., Gross-Goupil, M., … Sternberg, C. N. (2021). Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial. European Urology, 79(3), 334–338. https://doi.org/10.1016/j.eururo.2020.12.029

Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial

Abstract

Author supplied keywords

Cite

Register to see more suggestions